HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Keenan, A. M. Articles by Schlom, J. Search for Related Content PubMed PubMed Citation Articles by Keenan, A. M. Articles by Schlom, J.

Radioimmunoscintigraphy of Human Colon Cancer Xenografts in Mice with Radioiodinated Monoclonal Antibody B72.3

Correspondence: For reprints contact: Andrew M. Keenan, MD, Dept. of Nuclear Medicine, Building 10, Room 1C401, National Institutes of Health, Bethesda, MD 20205.

ABSTRACT

Monoclonal antibody B72.3 reacts with a tumor-associated antigen that is found on human breast and colon carcinomas in significantly higher concentration than in normal adult tissues. Intact B72.3 IgG was labeled with I-131 or I-125 and injected into athymic mice bearing xenografts of human colon cancer. Whole-body scintiphotos obtained with a pinhole collimator demonstrated tumor localization within 24 hr after intravenous administration, and the tumor-to-background ratio rose continuously for at lest 14 days. Progressive antibody accumulation was observed in the tumor during the first 3 days, but no significant normal organ localization was observed at any time. No localization was seen in control tumors, a human melanoma xenograft that lacks the antigen recognized by B72.3. The pharmacokinetics of this antibody in tumor-bearing mice suggest that I-131 B72.3 may be useful for radioimmunotherapy as well as radioimmunoscintigraphy of colon cancer in man.